DocetaxelLiver toxicity following an off-label use of docetaxel for metastatic hormone-naive prostate cancer: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1716卷 / 1期

关键词：

D O I：

10.1007/s40278-018-50920-5

中图分类号：

学科分类号：

摘要：

引用

页码：122 / 122

共 50 条

[1] CrizotinibLiver toxicity following off-label use: case report
Reactions Weekly, 2015, 1551 (1) : 92 - 92
[2] HydroxychloroquineCardiac toxicity following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 374 - 374
[3] VemurafenibSkin toxicity following off-label use: case report
Reactions Weekly, 2015, 1563 (1) : 212 - 212
[4] The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
Aoun, Fouad
El Rassy, Elie
Sleilaty, Ghassan
Assi, Tarek
Bakouny, Ziad
Kattan, Joseph
FUTURE ONCOLOGY, 2017, 13 (30) : 2785 - 2790
[5] Treatment of hormone-naive metastatic prostate cancer
Hamilou, Zineb
Saad, Fred
Fizazi, Karim
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 334 - 338
[6] CopanlisibDevelopment of resistance following an off-label use of copanlisib for metastatic breast cancer: case report
Reactions Weekly, 2020, 1812 (1) : 84 - 84
[7] Genomic landscape of metastatic hormone-naive prostate cancer
Mizuno, Kei
Akamatsu, Shusuke
Goto, Takayuki
Kobayashi, Takashi
Ogawa, Osamu
CANCER SCIENCE, 2021, 112 : 656 - 656
[8] In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet
Armstrong, Andrew J.
ONCOLOGY-NEW YORK, 2014, 28 (10): : 881 - +
[9] DecitabineHaematological toxicity and bacterial pneumonia following off-label use: case report
Reactions Weekly, 2020, 1786 (1) : 72 - 72
[10] RuxolitinibGrade 3 liver toxicity following off-label use: case report
Reactions Weekly, 2020, 1815 (1) : 293 - 293

← 1 2 3 4 5 →